GSK2292767

• CAT Number: M015632
• CAS Number: 1254036-66-2
• Molecular Formula: C24H28N6O5S
• Molecular Weight: 512.58
• Purity: ≥95%
• Synonyms: N-[5-[4-[5-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide
• IUPAC Name: N-[5-[4-[5-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide
• InChI: InChI=1S/C24H28N6O5S/c1-14-11-30(12-15(2)34-14)13-18-9-26-23(35-18)19-5-16(6-21-20(19)10-27-28-21)17-7-22(29-36(4,31)32)24(33-3)25-8-17/h5-10,14-15,29H,11-13H2,1-4H3,(H,27,28)/t14-,15+
• InChIKey: NLUPPCTVKHDVIQ-GASCZTMLSA-N
• SMILES: C[C@@H]1CN(C[C@@H](O1)C)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=CC(=C(N=C5)OC)NS(=O)(=O)C

GSK2292767（Cat No.:M015632）is a selective, inhaled phosphoinositide 3-kinase delta (PI3Kδ) inhibitor developed by GlaxoSmithKline for the treatment of respiratory inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). By targeting PI3Kδ, a key regulator of leukocyte activation and survival, GSK2292767 reduces airway inflammation, mucus production, and immune cell infiltration. Its inhaled formulation provides localized delivery to the lungs, minimizing systemic exposure and potential side effects. In research, GSK2292767 is a valuable tool for studying PI3Kδ-driven immune responses, airway remodeling, and therapeutic strategies in pulmonary disorders.